神经胶质瘤肿瘤抑制因子候选区基因1对前列腺癌细胞增殖及迁移能力的影响

Glioma tumor suppressor candidate region gene 1 enhances the proliferation and migration ability of prostate cancer

目的:探讨神经胶质瘤肿瘤抑制因子候选区基因1(GLTSCR1)对前列腺癌进展的影响及调控。方法:将前列腺癌细胞系DU145、LNCaP分别分为对照组(sh-NC),基因抑制组(sh-GLTSCR1),对照组使用慢病毒转染空白载体质粒,基因抑制组转染携带GLTSCR1短发卡RNA(shRNA)的质粒。细胞计数试剂盒(CCK-8)法检测吸光度(A)值评估细胞增殖能力,划痕实验检测细胞迁移能力。最后使用DU145细胞株在裸鼠皮下接种检测肿瘤大小、重量。采用t检验评估两组间差异。结果:在24、48、72 h时DU145-sh-GLTSCR1组A值低于对照组[(1.223±0.015、2.142±0.018、2.576±0.036)比(1.754±0.009、2.307±0.001、2.641±0.016),t=51.360,P<0.001;t=15.590,P<0.001;t=2.868,P<0.05],差异均有统计学意义;LNCaP-sh-GLTSCR1组A值低于对照组[(0.322±0.002、0.480±0.003、1.175±0.003)比(0.359±0.001、0.655±0.014、1.473±0.022),t=15.480、12.060、13.600,P<0.05],差异均有统计学意义。划痕实验结果显示DU145-sh-GLTSCR1组细胞24 h的愈合程度低于对照组[(0.446±0.030)比(0.543±0.053),t=3.915,P<0.01],差异有统计学意义。LNCaP-sh-GLTSCR1组细胞72 h的愈合程度低于对照组[(0.410±0.060)比(0.583±0.083),t=2.927,P<0.05],差异有统计学意义。小鼠皮下成瘤模型表明,敲低GLTSCR1组肿瘤重量低于对照组[(0.033±0.012)g比(0.083±0.022)g,t=1.987,P<0.05],差异有统计学意义。结论:GLTSCR1可促进前列腺癌细胞增殖及迁移。

Objective To investigate the effect of glioma tumor suppressor candidate region gene 1(GLTSCR1)on the progression of prostate cancer.Methods DU145 and LNCaP cells were transfected with blank vectoror or short hairpin RNA(shRNA)of GLTSCR1.Proliferation was detected by cell count kit,migration was detected by wound-scratch assays,and the effect of GLTSCR1 on prostate cancer in vivo was detected through cell derived xenograft(CDX)model with DU145.T test was used to evaluate the difference between the two groups.Results The proliferation of DU145 cells[absorbance(A),(1.223±0.015,2.142±0.018,2.576±0.036)vs.(1.754±0.009,2.307±0.001,2.641±0.016),t=51.360,P<0.05;t=15.590,P<0.05;t=2.868,P<0.05]and LNCaP cells[A:(0.3221±0.002,0.480±0.003,1.175±0.003)vs.(0.359±0.001,0.655±0.014,1.473±0.022),t=15.480,12.060,13.600,all P<0.01]was suppressed in sh-GLTSCR1 group at 24,48 and 72 h.The migration index in DU145-sh-GLTSCR1 group[(0.446±0.030)vs.(0.543±0.053),t=3.915,P<0.01]and LNCaP-sh-GLTSCR1 group[(0.410±0.060)vs.(0.583±0.083),t=2.927,P<0.05]was lower than in control group.CDX model suggested that the tumor burden in the sh-GLTSCR1 group was lower than in control group[(0.033±0.012)g vs.(0.083±0.022)g,t=1.987,P<0.05].Conclusion GLTSCR1 enhances the proliferation and migration of prostate cancer.